

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q85692

Hiromu HABASHITA, et al.

Appln. No.: 10/520,660

Group Art Unit: 1624

Confirmation No.: 7023

Examiner: Jeffrey Murray

Filed: January 10, 2005

For: CCR4 ANTAGONIST AND MEDICAL USE THEREOF

**RESPONSE TO RESTRICTION REQUIREMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This responds to the Restriction Requirement dated December 11, 2007 to which Applicants elect for examination Group I, the compound or composition of general formula (I), wherein D is 1,4-diazine, bonded to an oxygen linker J and also bonded to sulfonamide linker B according to claims 1-33, 35-43 and 46-49. This election is made without traverse.

Applicants reserve the right to file a Divisional Application(s) directed to the compounds or compositions of general formula (I), not described in elected Group I, and for non-elected claims 34, 44 and 45.

However, Applicants request clarification about the status of claim 45 as it was canceled in the Preliminary Amendment filed on August 30, 2005.

RESPONSE TO RESTRICTION REQUIREMENT

Attorney Docket No.: Q85692

U.S. Application No.: 10/520,660

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

/Sunhee Lee/

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

**65565**

CUSTOMER NUMBER

---

Sunhee Lee

Registration No. 53,892

Date: January 10, 2008